Overview
TARS market data
Price History
TARS price chart · 1M
- O
- 70.41
- H
- 71.08
- L
- 70.23
- C
- 70.58
- Vol
- 30,833.00
- Source
- US equities market feed
- Observed
- Aug 26, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $70.41
- Previous Close
- $71.47
- Day High
- $71.08
- Day Low
- $70.23
- 52 Week High
- $75.20
- 52 Week Low
- $54.18
- 7 Day Return
- -3.86%
- 30 Day Return
- +17.46%
- 90 Day Return
- +18.60%
- 1 Year Return
- -3.66%
- Daily Notional Volume
- $2.2M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.59 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.44 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -7.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $48.20 – $85.25 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3B · P/B 10.12 · P/S 4.99.
Company News
Alkeus Pharmaceuticals Receives Orphan Drug Designation From Japan's Ministry Of Health, Labour, And Welfare For Oral Gildeuretinol To Treat Stargardt DiseaseBenzinga · Aug 24, 2026, 1:28 PM
Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100Benzinga · Aug 12, 2026, 3:16 PM
Tarsus Pharmaceuticals Q2 EPS $(0.43) Misses $(0.20) Estimate, Sales $173.912M Beat $169.677M EstimateBenzinga · Aug 6, 2026, 9:41 PM
Tarsus Pharmaceuticals Announces Agreement To Acquire Alkeus For $450M Upfront In Cash And Stock, Up To $350M In Milestones, Adding Phase 3 Stargardt Disease TherapyBenzinga · Aug 6, 2026, 11:23 AM
8-K filing — Tarsus Pharmaceuticals, Inc. (TARS)SEC EDGAR · Aug 6, 2026, 11:23 AM
Tarsus Pharmaceuticals To Acquire Alkeus Pharmaceuticals, A Closely Held Biotech Firm Developing Gildeuretinol, An Investigational Once-Daily Oral Therapy For Stargardt Disease; Terms Not DisclosedBenzinga · Aug 6, 2026, 11:16 AM
Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026Globenewswire Inc · Aug 6, 2026, 11:15 AM
Mizuho Maintains Outperform on Tarsus Pharmaceuticals, Lowers Price Target to $98Benzinga · Jul 31, 2026, 5:40 PM
Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $89Benzinga · Jul 21, 2026, 1:56 PM
Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye DrugBenzinga · Jul 9, 2026, 5:05 PM